Abstract
The disclosure provides a pharmaceutical composition for phosphodiesterase 4-mediated disease treatment of patient and inhibition of phosphodiesterase 4 activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The disclosure further provides a use of the Ribociclib for manufacturing the pharmaceutical composition for phosphodiesterase 4-mediated disease treatment of patient. The application of the pharmaceutical composition and the use of the present invention are advantageous for inhibiting of phosphodiesterase 4 activity and thus treating a phosphodiesterase 4-mediated disease.
Translated title of the contribution | PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT |
---|---|
Original language | Chinese (Traditional) |
IPC | A61K 31/519(2006.01); A61P 37/00(2006.01); C07D 471/04(2006.01) |
State | Published - 01 01 2021 |
Bibliographical note
公開公告號: 2.02100158E8Announcement ID: 2.02100158E8